Wang Wei, Rayburn Elizabeth R, Zhao Yuqing, Wang Hui, Zhang Ruiwen
Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, and Comprehensive Cancer Center, University of Alabama at Birmingham, VH 113, Box 600, 1670 University Blvd., Birmingham, AL 35294, USA.
Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, and Comprehensive Cancer Center, University of Alabama at Birmingham, VH 113, Box 600, 1670 University Blvd., Birmingham, AL 35294, USA; Department of Gene Therapy, University of Alabama at Birmingham, Birmingham, AL, USA.
Cancer Lett. 2009 Jun 18;278(2):241-248. doi: 10.1016/j.canlet.2009.01.005. Epub 2009 Feb 8.
We recently isolated and characterized two novel ginsenosides, 25-OH-PPD and 25-OCH(3)-PPD. We investigated whether these ginsenosides could represent safe and effective therapeutic agents for pancreatic cancer. In vitro and in vivo studies demonstrated that both compounds inhibited proliferation, caused cell cycle arrest, and induced apoptosis. They also both inhibited the growth of xenograft tumors without any host toxicity. Preliminary investigations into the mechanisms of action of the compounds suggest that their effects may be partially mediated by their inhibition of the MDM2 oncogene and related pathways. The data presented here support further evaluation of the ginsenosides for pancreatic cancer therapy.
我们最近分离并鉴定了两种新型人参皂苷，25-羟基原人参二醇（25-OH-PPD）和25-甲氧基原人参二醇（25-OCH(3)-PPD）。我们研究了这些人参皂苷是否可作为胰腺癌安全有效的治疗药物。体外和体内研究表明，这两种化合物均能抑制增殖、导致细胞周期停滞并诱导凋亡。它们还均能抑制异种移植肿瘤的生长，且无任何宿主毒性。对这些化合物作用机制的初步研究表明，其作用可能部分是通过抑制MDM2癌基因及相关途径介导的。本文提供的数据支持对这些人参皂苷用于胰腺癌治疗进行进一步评估。
